Escherichia coli-Derived Outer Membrane Vesicles Deliver Galactose- 1-Phosphate Uridyltransferase and Yield Partial Protection against Actinobacillus pleuropneumoniae in Mice
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
In our previous studies, we have identified several in vivo-induced antigens and evaluated their potential as subunit vaccine candidates in a murine model, in which the recombinant protein GalT showed the most potent immunogenicity and immunoprotective efficacy against Actinobacillus pleuropneumoniae. To exploit a more efficient way of delivering GalT proteins, in this study, we employed the widely studied E. coli outer membrane vesicles (OMVs) as a platform to deliver GalT protein and performed the vaccine trial using the recombinant GalTOMVs in the murine model. Results revealed that GalT-OMVs could elicit a highly-specific, IgG antibody titer that was comparable with the adjuvant GalT group. Significantly higher lymphocyte proliferation and cytokines secretion levels were observed in the GalT-OMVs group. 87.5% and 50% of mice were protected from a lethal dose challenge using A. pleuropneumoniae in active or passive immunization, respectively. Histopathologic and immunohistochemical analyses showed remarkably reduced pathological changes and infiltration of neutrophils in the lungs of mice immunized with GalT-OMVs after the challenge. Taken together, these findings confirm that OMVs can be used as a platform to deliver GalT protein and enhance its immunogenicity to induce both humoral and cellular immune responses in mice.
Abstract
In our previous studies, we have identified several in vivo-induced antigens and evaluated their potential as subunit vaccine candidates in a murine model, in which the recombinant protein GalT showed the most potent immunogenicity and immunoprotective efficacy against Actinobacillus pleuropneumoniae. To exploit a more efficient way of delivering GalT proteins, in this study, we employed the widely studied E. coli outer membrane vesicles (OMVs) as a platform to deliver GalT protein and performed the vaccine trial using the recombinant GalTOMVs in the murine model. Results revealed that GalT-OMVs could elicit a highly-specific, IgG antibody titer that was comparable with the adjuvant GalT group. Significantly higher lymphocyte proliferation and cytokines secretion levels were observed in the GalT-OMVs group. 87.5% and 50% of mice were protected from a lethal dose challenge using A. pleuropneumoniae in active or passive immunization, respectively. Histopathologic and immunohistochemical analyses showed remarkably reduced pathological changes and infiltration of neutrophils in the lungs of mice immunized with GalT-OMVs after the challenge. Taken together, these findings confirm that OMVs can be used as a platform to deliver GalT protein and enhance its immunogenicity to induce both humoral and cellular immune responses in mice.
참고문헌 (45)
- Li Y, "A TolC-like protein of Actinobacillus pleuropneumoniae is involved in antibiotic resistance and biofilm formation", Front. Microbiol, 7, pp.1618~ (2016)
- Bosse JT, "The generation of successive unmarked mutations and chromosomal insertion of heterologous genes in Actinobacillus pleuropneumoniae using natural transformation", PLoS One, 9, pp.e111252~ (2014)
- Cuccui J, "The N-linking glycosylation system from Actinobacillus pleuropneumoniae i s requ ired f or adhesion and has potential use in glycoengineering", Open Biol, 7 (2017)
- Zhu Z, "Polyamine-binding protein PotD2 is required for stress tolerance and virulence in Actinobacillus pleuropneumoniae", Antonie van Leeuwenhoek, 110, pp.1647~1657 (2017)
- Sárközi R, "Identification of a proposed new serovar of Actinobacillus pleuropneumoniae:serovar 16", Acta Vet. Hung, 63, pp.444~450 (2015)
- Bossé J, "Proposal of serovars 17 and 18 of Actinobacillus pleuropneumoniae based on serological and genotypic analysis", Vet. Microbiol, 217, pp.1~6 (2018)
- Oldfield NJ, "Identification and characterization of novel antigenic vaccine candidates of Actinobacillus pleuropneumoniae", Vaccine, 26, pp.1942~1954 (2008)
- Chiang CH, "Immunogenicity and protective efficacy of ApxIA and ApxIIA DNA vaccine against Actinobacillus pleuropneumoniae lethal challenge in murine model", Vaccine, 27, pp.4565~4570 (2009)
- Lu YC, "DNA vaccine encoding type IV pilin of Actinobacillus pleuropneumoniae induces strong immune response but confers limited protective efficacy against serotype 2 challenge", Vaccine, 29, pp.7740~7746 (2011)
- Bei W, "Evaluation of immunogenicity and protective efficacy of Actinobacillus pleuropneumoniae HB04C(-) mutant lacking a drug resistance marker in the pigs", Vet. Microbiol, 125, pp.120~127 (2007)
- Chen DJ, "Delivery of foreign antigens by engineered outer membrane vesicle vaccines", Proc. Natl. Acad. Sci. USA, 107, pp.3099~3104 (2010)
- Abbas AK, "Basic Immunology", pp.36~42 (2012), Saunders
- Schwechheimer C, "Outer-membrane vesicles from Gram-negative bacteria: biogenesis and functions", Nat. Rev. Microbiol, 13, pp.605~619 (2015)
- Schertzer JW, "A bilayer-couple model of bacterial outer membrane vesicle biogenesis", MBio, 3, pp.203~216 (2012)
- Kulp A, "Biological functions and biogenesis of secreted bacterial outer membrane vesicles", Annu. Rev. Microbiol, 64, pp.163~184 (2010)
- Mashburn-Warren LM, "Special delivery:vesicle trafficking in prokaryotes", Mol. Microbiol, 61, pp.839~846 (2006)
- Kuehn MJ, "Bacterial outer membrane vesicles and the host–pathogen interaction", Genes Dev, 19, pp.2645~2655 (2005)
- Lee EY, "Proteomics in gram-negative bacterial outer membrane vesicles", Mass Spectrom. Rev, 27, pp.535~555 (2008)
- Fulsundar S, "Gene transfer potential of outer membrane vesicles of Acinetobacter baylyi and effects of stress on vesiculation", Appl. Environ. Microbiol, 80, pp.3469~3483 (2014)
- Yaron S, "Vesiclemediated transfer of virulence genes from Escherichia coli O157:H7 to other enteric bacteria", Appl. Environ. Microbiol, 66, pp.4414~4420 (2000)
- Schooling SR, "Membrane vesicles: an overlooked component of the matrices of biofilms", J. Bacteriol, 188, pp.5945~5957 (2006)
- van der Pol L, "Outer membrane vesicles as platform vaccine technology", Biotechnol. J, 10, pp.1689~1706 (2015)
- Ellis TN, "Virulence and immunomodulatory roles of bacterial outer membrane vesicles", Microbiol. Mol. Biol. Rev, 74, pp.81~94 (2010)
- Kleijn EDD, "Immunogenicity and safety of a hexavalent meningococcal outer-membrane-vesicle vaccine in children of 2–3 and 7–8 years of age", Vaccine, 18, pp.1456~1466 (2000)
- Sandbu S, "Immunogenicity and safety of a combination of two serogroup B meningococcal outer membrane vesicle vaccines", Clin. Vaccine Immunol, 14, pp.1062~1069 (2007)
- Wai SN, "Vesicle-mediated export and assembly of pore-forming oligomers of the enterobacterial ClyA cytotoxin", Cell, 115, pp.25~35 (2003)
- Rappazzo CG, "Recombinant M2e outer membrane vesicle vaccines protect against lethal influenza A challenge in BALB", c mice, 2016, pp.34, 1252~1258
- Huang W, "Employing Escherichia coli-derived outer membrane vesicles as an antigen delivery platform elicits protective immunity against Acinetobacter baumannii infection", Sci. Rep, 6, pp.37242~ (2016)
- Zhang F, "Immunoprotective efficacy of six in vivo-induced antigens against Actinobacillus pleuropneumoniae as potential vaccine candidates in murine model", Front. Microbiol, 7, pp.728~732 (2016)
- Fei Zhang, "Identification of Actinobacillus pleuropneumoniae Genes Preferentially Expressed During Infection Using In Vivo-Induced Antigen Technology (IVIAT)", Journal of Microbiology and Biotechnology, 25(10), pp.1606~1613 (2015), 한국미생물·생명공학회[DOI]
- Zhang F, "Galactose-1-phosphate uridyltransferase (GalT), an in vivo-induced antigen of Actinobacillus pleuropneumoniae serovar 5b strain L20, provided immunoprotection against serovar 1 strain MS71", PLoS One, 13, pp.e0198207~ (2018)
- Kim JY, "Engineered bacterial outer membrane vesicles with enhanced functionality", J. Mol. Biol, 380, pp.51~66 (2008)
- Fu S, "Immunogenicity and protective efficacy of recombinant Haemophilus parasuis SH0165 putative outer membrane proteins", Vaccine, 31, pp.347~353 (2012)
- Li M, "Identification of secreted proteins as novel antigenic vaccine candidates of Haemophilus parasuis serovar 5", Vaccine, 33, pp.1695~1701 (2015)
- Oh Y, "Expression of leucocyte function-associated antigen-1 and intercellular adhesion molecule-1 in the lungs of pigs infected with Actinobacillus pleuropneumoniae", J. Comp. Pathol, 148, pp.259~265 (2013)
- Bachmann MF, "Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns", Nat. Rev. Immunol, 10, pp.787~796 (2010)
- Mccaig WD, "Characterization and vaccine potential of outer membrane vesicles produced by Haemophilus parasuis", PLoS One, 11, pp.e0149132~ (2016)
- Stevenson TC, "Immunization with outer membrane vesicles displaying conserved surface polysaccharide antigen elicits broadly antimicrobial antibodies", Proc. Natl. Acad. Sci. USA, 115, pp.201718341~ (2018)
- Asensio CJ, "Outer membrane vesicles obtained from Bordetella pertussis Tohama expressing the lipid A deacylase PagL as a novel acellular vaccine candidate", Vaccine, 29, pp.1649~1656 (2011)
- Sierra GV, "Vaccine against g roup B Neisseria meningitidis: protection trial and mass vaccination results in Cuba", NIPH Ann, 14, pp.195~207 (1991)
- Xu K, "A trivalent Apx-fusion protein delivered by E. coli o u ter membrane vesicles induce protection against Actinobacillus pleuropneumoniae of serotype 1 and 7 challenge in a murine model", PLoS One, 13, pp.e0191286~ (2018)
- Zhao K, "Pseudomonas aeruginosa outer membrane vesicles modulate host immune responses by targeting the toll-like receptor 4 signaling pathway", Infect. Immun, 81, pp.4509~4518 (2013)
- Fransen F, "Differential effect of TLR2 and TLR4 on the immune response after immunization with a vaccine against Neisseria meningitidis or Bordetella pertussis", PLoS One, 5, pp.e15692~ (2010)
- Chen L, "Outer membrane vesicles displaying engineered glycotopes elicit protective antibodies", Proc. Natl. Acad. Sci. USA, 113, pp.E3609~E3618 (2016)
- Kim SH, "Structural modifications of outer membrane vesicles to refine them as vaccine delivery vehicles", Biochim. Biophys. Acta, 1788, pp.2150~2159 (2009)